"LGS is a severely disabling condition. Some of these children have very frequent seizures – up to several a day – despite high doses of multiple antiepileptic medications. eTNS is a promising new approach to the treatment of drug-resistant epilepsy in general, and we are eager to find out whether it could be helpful in this very challenging subset of patients," said Dr. Shewmon.
"Children with LGS are often severely drug resistant, and continue to have frequent seizures despite trying multiple antiepileptic medications, often in combination. These children can be injured when they fall during drop attacks, a problem that frequently persists into adulthood. Helping children and their families deal with the symptoms and the severe disability of LGS represents a significant unmet clinical need," added Christopher DeGiorgio, M.D., NeuroSigma's Vice President of Neurology and the Professor of Neurology at UCLA who first investigated eTNS for DRE. "Recent data from European clinical use of our eTNS therapy suggests that it is safe to use in children, and we're eager to learn what benefits can be detected with eTNS therapy in children with LGS."
"We are delighted that Dr. Shewmon and his collaborators at Olive View have begun enrolling children into this trial. Besides possibly affording better control of seizures, our adjunctive treatment may lessen the need for antiepileptic drugs and thus allow children to avoid the medication side effects that can interfere with schoolwork and social development," noted Leon Ekchian, Ph.D., NeuroSigma's President and CEO.
Background – The Monarch eTNS System from NeuroSigma
In August 2012, NeuroSigma received CE Mark approval to market NeuroSigma's first trigeminal nerve stimulation (TNS) product, the Monarch™ eTNS™ System, in the European Union, for the adjunctive treatment of ep
Copyright©2014 PR Newswire.
All rights reserved